Zheng Quan Shi Bao·2025-09-06 00:17Core Viewpoint - The pharmaceutical and technology sectors continue to receive positive attention from institutional investors, with significant interest in specific stocks and a favorable outlook for the pharmaceutical industry due to recent policy changes and innovation [1][2]. Group 1: Institutional Ratings and Sector Performance - A total of 59 institutions conducted 1,678 "buy" ratings covering 929 stocks from September 1 to September 5, with the pharmaceutical sector having 94 stocks rated positively [2]. - The pharmaceutical industry is transitioning from "Made in China" to "Created in China," with a strong performance expected in the coming quarters due to the commercialization of innovative products and overseas expansion potential [2]. - 51 stocks received attention from five or more institutions, with major companies like Midea Group and Great Wall Motors leading in institutional interest [2]. Group 2: Company Performance Highlights - Midea Group reported a net profit of 26.014 billion yuan for the first half of the year, a year-on-year increase of 25.04%, marking the highest growth rate since 2016 [4]. - BYD's net profit increased by nearly 14% in the first half of the year, with new factories in Brazil and Thailand contributing to its growth [4]. - Companies in the food and beverage sector, including Luzhou Laojiao, Wuliangye, Shanxi Fenjiu, and Haitian Flavoring, also received multiple "buy" ratings from institutions [4]. Group 3: Shareholder Concentration and Stock Performance - Among the stocks rated "buy," 89 saw a decrease in shareholder numbers compared to the end of the second quarter, with 41 stocks experiencing a decline of over 10% [5]. - Igor's shareholder count dropped by nearly 38%, while the company achieved a revenue of 2.467 billion yuan, a year-on-year increase of 20.16% [5]. - The average increase in stock prices for the 41 stocks with concentrated holdings exceeded 20%, with six stocks, including Aosaikang and Tengya Precision, seeing gains over 50% [7]. Group 4: Underperforming Stocks - 15 stocks underperformed compared to the Shanghai Composite Index, with Zhejiang Dingli experiencing the largest decline of nearly 18% despite a net profit increase of 27.63% [8]. - Wuliangye and ZTE both received "buy" ratings from six institutions, with Wuliangye's stock price down over 5% year-to-date [8][9]. - ZTE's shareholder count decreased by over 14%, with a net profit decline of nearly 12% in the first half of the year, although revenue grew by 14.51% [9].